Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market by Therapeutics (Marketed Drugs-(NMDA Receptor Antagonists, Cholinesterase Inhibitors), Pipeline Drugs), by Diagnostics (Computed tomography scan, Electroencephalography, Lumbar puncture test, Magnetic resonance imaging, Positron emission tomography, and Others) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market by Therapeutics (Marketed Drugs-(NMDA Receptor Antagonists, Cholinesterase Inhibitors), Pipeline Drugs), by Diagnostics (Computed tomography scan, Electroencephalography, Lumbar puncture test, Magnetic resonance imaging, Positron emission tomography, and Others) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

ID: 2250 | Pages: 138 | May 2017 | Region: Asia Pacific


The Asia-Pacific Alzheimer’s disease Therapeutics and Diagnostics Market was worth USD 2.29 billion in 2016 and estimated to be growing at a CAGR of 5.02%, to reach USD 2.93 billion by 2021. Alzheimer’s disease is a neurodegenerative, progressive, non-reversible ailment that is caused due to irregular functioning of brain cells i.e. breakdown of synaptic communication, ensuing in the loss of cerebral functions.

Certain signs and indications of Alzheimer’s disease are memory loss, sleeplessness, recurring movements, anxiety, despair and loss of reasoning capabilities. All memory and cerebral functioning may be lost in the advanced stages of the disease. According to the International Institute of Aging, Alzheimer’s disease is the most frequent form of dementia.

The growth of the Asia-Pacific Alzheimer’s disease Therapeutics and Diagnostics Market is mainly driven by factors such as rising geriatric populace, upsurge in healthcare spending and increasing government subsidy. In addition, growing healthcare cognizance and innovative diagnostic technologies are also stimulating the growth of the market. However, several factors such as stringent regulations, long authorization time for new medicines, and expiration of numerous patent drugs are restraining the growth of the Alzheimer’s disease Therapeutics and Diagnostics market in this region.

The Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics market is segmented based on Therapeutics and Diagnostics. The market for Alzheimer’s disease Therapeutics and Diagnostics, on the basis of Therapeutics is segmented into Marketed Drugs and Pipeline Drugs. Marketed Drugs are further segmented into NMDA Receptor Antagonists and Cholinesterase Inhibitors. Marketed Drugs lead the market on the basis of Therapeutics due to a large user base. On the basis of Diagnostics, the Alzheimer’s disease Therapeutics and Diagnostics market is segmented into Computed tomography scan, Electroencephalography, Lumbar puncture test, Magnetic resonance imaging, Positron emission tomography, and Others. Under this segment, Computed tomography scan segment leads the Alzheimer’s disease Therapeutics and Diagnostics market. Absence of alternative imaging tool for brain and neurological diagnostics is one of the crucial reasons for its large share.

The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. Developing countries are anticipated to offer lucrative prospects for this market in this region. According to Alzheimer’s disease International in 2015, 58% of people with dementia live in emerging countries, but by 2050 this figure will rise to 68%. The fastest growth in the elderly populace is taking place in China, India, and their south Asian and western Pacific region.

Leading companies have applied tactics such as mergers & acquisitions, collaborations, and joint ventures to gain a strong foothold in the market. The major companies dominating the Alzheimer’s Disease Therapeutics and Diagnostics market in this region are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare, Janssen Pharmaceuticals etc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapeutics                              

                                5.1.1 Introduction           

                                5.1.2 Marketed Drugs   

                                                5.1.2.1 NMDA Receptor Antagonists

                                                5.1.2.2 Cholinesterase Inhibitors

                                5.1.3 Pipeline Drugs       

                                5.1.4  Y-o-Y Growth Analysis, By Therapeutics    

                                5.1.5  Market Attractiveness Analysis, By Therapeutics  

                                5.1.6  Market Share Analysis, By Therapeutics    

                5.2 Diagnostics                 

                                5.2.1 Introduction           

                                5.2.2 Computed tomography scan           

                                5.2.3 Electroencephalography   

                                5.2.4 Lumbar puncture test        

                                5.2.5 Magnetic resonance imaging          

                                5.2.6 Positron emission tomography      

                                5.2.7 Others      

                                5.2.8  Y-o-Y Growth Analysis, By Diagnostics        

                                5.2.9  Market Attractiveness Analysis, By Diagnostics      

                                5.2.10  Market Share Analysis, By Diagnostics     

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Therapeutics

                                                6.1.3.3 By Diagnostics

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Therapeutics

                                                6.1.4.3 By Diagnostics

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Therapeutics

                                                6.1.5.3 By Diagnostics

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Abbvie Inc.                 

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Pfizer Inc.                    

                8.3 AC Immune SA                          

                8.4 Eisai Co Ltd.                

                8.5 Allergan PLC                               

                8.6 Novartis AG                

                8.7 Amarantus Bioscience Holdings                         

                8.8 H. Lundbeck A/S                       

                8.9 Anavex LifeSciencescs                           

                8.10 Avid Radiopharmaceuticals                               

                8.11 Forest Laboratories Inc.                      

                8.12 Axon Neuroscience                              

                8.13 Daiichi Sankyo Co                   

                8.14 TauRx Therapeutics Ltd                       

                8.15 Eli Lilly                         

                8.16 F. Hoffmann La Roche AG                  

                8.17 Johnson & Johnson                              

                8.18 GE Healthcare                         

                8.19 Janssen Pharmaceuticals                    

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2016-2021 ( USD Billion )
  2. Asia-Pacific Marketed Drugs Market By Region, From 2016-2021 ( USD Billion )
  3. Asia-Pacific Pipeline Drugs Market By Region, From 2016-2021 ( USD Billion )
  4. Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2016-2021 ( USD Billion )
  5. Asia-Pacific Computed tomography scan Market By Region, From 2016-2021 ( USD Billion )
  6. Asia-Pacific Electroencephalography Market By Region, From 2016-2021 ( USD Billion )
  7. Asia-Pacific Lumbar puncture test Market By Region, From 2016-2021 ( USD Billion )
  8. Asia-Pacific Magnetic resonance imaging Market By Region, From 2016-2021 ( USD Billion )
  9. Asia-Pacific Positron emission tomography Market By Region, From 2016-2021 ( USD Billion )
  10. Asia-Pacific Other diagnostics Market By Region, From 2016-2021 ( USD Billion )
  11. Japan Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2016-2021 ( USD Billion )
  12. Japan Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2016-2021 ( USD Billion )
  13. China Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2016-2021 ( USD Billion )
  14. China Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2016-2021 ( USD Billion )
  15. India Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2016-2021 ( USD Billion )
  16. India Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2016-2021 ( USD Billion )
  17. Australia Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2016-2021 ( USD Billion )
  18. Australia Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2016-2021 ( USD Billion )
  19. South Korea Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2016-2021 ( USD Billion )
  20. South Korea Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2016-2021 ( USD Billion )
  21. Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2016-2021 ( USD Billion )
  22. Asia-Pacific NMDA Receptor Antagonists Market By Region, From 2016-2021 ( USD Billion )
  23. Asia-Pacific Cholinesterase Inhibitors Market By Region, From 2016-2021 ( USD Billion )
  24. Japan Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2016-2021 ( USD Billion )
  25. China Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2016-2021 ( USD Billion )
  26. India Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2016-2021 ( USD Billion )
  27. Australia Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2016-2021 ( USD Billion )
Middle-East And Africa Cell Counting Market By Product [(Instruments (Cell Counters, Hematology Analysers, Spectrophotometer, Flow Cytometer, Hemocytometer, Others), Consumables (Microplates, Reagent, Assay Kits)], ...
Latin America Cell Counting Market By Product [(Instruments (Cell Counters, Hematology Analysers, Spectrophotometer, Flow Cytometer, Hemocytometer, Others), Consumables (Microplates, Reagent, Assay Kits)], End User ...
Asia-Pacific Cell Counting Market By Product [(Instruments (Cell Counters, Hematology Analysers, Spectrophotometer, Flow Cytometer, Hemocytometer, Others), Consumables (Microplates, Reagent, Assay Kits)], End User (...
Europe Cell Counting Market By Product [(Instruments (Cell Counters, Hematology Analysers, Spectrophotometer, Flow Cytometer, Hemocytometer, Others), Consumables (Microplates, Reagent, Assay Kits)], End User (Pharma...
North America Cell Counting Market By Product [(Instruments (Cell Counters, Hematology Analysers, Spectrophotometer, Flow Cytometer, Hemocytometer, Others), Consumables (Microplates, Reagent, Assay Kits)], End User ...
Cell Counting Market By Product [(Instruments (Cell Counters, Hematology Analysers, Spectrophotometer, Flow Cytometer, Hemocytometer, Others), Consumables (Microplates, Reagent, Assay Kits)], End User (Pharmaceutica...
Middle East And Africa Non-Invasive Cancer Diagnostics Market By Techniques (Clinical Chemistry, Immunochemistry, Molecular Diagnostics And Others), By Therapeutics (Blood Cancer, Breast Cancer, Lung Cancer, Solid T...
Latin America Non-Invasive Cancer Diagnostics Market By Techniques (Clinical Chemistry, Immunochemistry, Molecular Diagnostics And Others), By Therapeutics (Blood Cancer, Breast Cancer, Lung Cancer, Solid Tumors And...
Asia Pacific Non-Invasive Cancer Diagnostics Market By Techniques (Clinical Chemistry, Immunochemistry, Molecular Diagnostics And Others), By Therapeutics (Blood Cancer, Breast Cancer, Lung Cancer, Solid Tumors And ...
Europe Non-Invasive Cancer Diagnostics Market By Techniques (Clinical Chemistry, Immunochemistry, Molecular Diagnostics And Others), By Therapeutics (Blood Cancer, Breast Cancer, Lung Cancer, Solid Tumors And Others...
North America Non-Invasive Cancer Diagnostics Market By Techniques (Clinical Chemistry, Immunochemistry, Molecular Diagnostics And Others), By Therapeutics (Blood Cancer, Breast Cancer, Lung Cancer, Solid Tumors And...
Non-Invasive Cancer Diagnostics Market By Techniques (Clinical Chemistry, Immunochemistry, Molecular Diagnostics And Others), By Therapeutics (Blood Cancer, Breast Cancer, Lung Cancer, Solid Tumors And Others) And B...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.